Company intelligence / Profile preview

Second Nature

London, England, United Kingdomsecondnature.com ↗

Ownership: Private
Employees: ~80
Development stage: Commercial

Overview

Analysis from a group of 10,000 participants revealed an average weight loss of 5.9 kg at the 12-week mark. Peer-reviewed data showed much of this weight loss was sustained at the six-month and twelve-month marks—a key indicator of long-term beneficial lifestyle change

Therapeutic areas: Endocrinology
Modalities: Non-pharmacological therapyDigital therapeutics
Industry: Digital Health Medical Devices

Partnerships

NHS England (commissioned as first ‘lifestyle change programme’ for diabetes)

Beyond the preview

Go deeper on Second Nature.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Second Nature.

Explore the full profile